Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies
-
Published:2019-12
Issue:4
Volume:38
Page:625-642
-
ISSN:0167-7659
-
Container-title:Cancer and Metastasis Reviews
-
language:en
-
Short-container-title:Cancer Metastasis Rev
Author:
Knott Maximilian M. L.,Hölting Tilman L. B.,Ohmura Shunya,Kirchner Thomas,Cidre-Aranaz Florencia,Grünewald Thomas G. P.
Abstract
AbstractWhile sarcomas account for approximately 1% of malignant tumors of adults, they are particularly more common in children and adolescents affected by cancer. In contrast to malignancies that occur in later stages of life, childhood tumors, including sarcoma, are characterized by a striking paucity of somatic mutations. However, entity-defining fusion oncogenes acting as the main oncogenic driver mutations are frequently found in pediatric bone and soft-tissue sarcomas such as Ewing sarcoma (EWSR1-FLI1), alveolar rhabdomyosarcoma (PAX3/7-FOXO1), and synovial sarcoma (SS18-SSX1/2/4). Since strong oncogene-dependency has been demonstrated in these entities, direct pharmacological targeting of these fusion oncogenes has been excessively attempted, thus far, with limited success. Despite apparent challenges, our increasing understanding of the neomorphic features of these fusion oncogenes in conjunction with rapid technological advances will likely enable the development of new strategies to therapeutically exploit these neomorphic features and to ultimately turn the “undruggable” into first-line target structures. In this review, we provide a broad overview of the current literature on targeting neomorphic features of fusion oncogenes found in Ewing sarcoma, alveolar rhabdomyosarcoma, and synovial sarcoma, and give a perspective for future developments.
Funder
Ludwig-Maximilians-Universität München
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference207 articles.
1. Heisterkamp, N., Stephenson, J. R., Groffen, J., Hansen, P. F., de Klein, A., Bartram, C. R., & Grosveld, G. (1983). Localization of the c- abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature, 306(5940), 239–242. https://doi.org/10.1038/306239a0. 2. Groffen, J., Stephenson, J. R., Heisterkamp, N., de Klein, A., Bartram, C. R., & Grosveld, G. (1984). Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell, 36(1), 93–99. https://doi.org/10.1016/0092-8674(84)90077-1. 3. Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., … Rouleau, G. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature, 359(6391), 162–165. https://doi.org/10.1038/359162a0 4. Mitelman F, Johansson B and Mertens F (Eds.). (2019). Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Retrieved from https://mitelmandatabase.isb-cgc.org. Accessed 29 October 2019 5. Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015). The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene, 34(37), 4845–4854. https://doi.org/10.1038/onc.2014.406.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|